Get started
Author

Troy D. Patterson

Observed name: Troy Patterson
OpenAlex ID: A5028512226
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2016 · Kaiming Sun, Ruzanna Atoyan, et al. · Molecular Cancer Therapeutics · 143
Discovery of a Novel Class of Dimeric Smac Mimetics as Potent IAP Antagonists Resulting in a Clinical Candidate for the Treatment of Cancer (AZD5582)
2013 · Edward J. Hennessy, Ammar Adam, et al. · Journal of Medicinal Chemistry · 120
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer
2017 · Adam S. Lazorchak, Troy Patterson, et al. · Cancer Immunology Research · 11
A precision gene-engineered B cell medicine producing sustained levels of active factor IX for hemophilia B therapy
2025 · Hanlan Liu, Swati Singh, et al. · Molecular Therapy · 8
Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy
2025 · Lindsay Webb, Michael Lofgren, et al. · Frontiers in Immunology · 7
PDF
Development of an Ex Vivo Precision Gene Engineered B Cell Medicine That Produces Active and Sustained Levels of FIX for the Treatment of Hemophilia B
2023 · Hanlan Liu, Swati Singh, et al. · Blood · 5
A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics
2024 · Anja F Hohmann, Timothy Mullen, et al. · Blood · 1
203 A membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence and efficacy of CD70-targeted TRuC-T cells
2021 · Jian Ding, Lindsay Webb, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract 2190: Engineering off-the-shelf T cell receptor fusion construct (TRuC) T cells
2020 · Julie Donaghey, Philippe Kieffer-Kwon, et al. · Cancer Research · 1
Engineering Phospholipase A2 Receptor Fc-Fusions with Reduced Heparin Interaction Improves Pharmacokinetic Properties
2026 · Joseph R. Jacobowitz, Amoolya Palanati, et al. · Journal of the American Society of Nephrology
Selective Clearance of Phospholipase A2 Receptor (PLA2R) Autoantibodies for the Treatment of Experimental Membranous Nephropathy
2026 · Larissa Seifert, Lawrence Schweitzer, et al. · Journal of the American Society of Nephrology
Supplemental Figure 1-8 from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023 · Kaiming Sun, Ruzanna Atoyan, et al.
Supplement Figure Legends from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023 · Kaiming Sun, Ruzanna Atoyan, et al.
Data from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023 · Kaiming Sun, Ruzanna Atoyan, et al.
Data from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023 · Kaiming Sun, Ruzanna Atoyan, et al.
Abstract 557: Engineering off-the-shelf anti mesothelin t-cell receptor fusion construct (TRuC™) t-cells
2022 · Julie Donaghey, Cecilia Kwong, et al. · Cancer Research
Abstract 1514: Engineering off-the-shelf T Cell Receptor Fusion Construct (TRuC) T cells
2021 · Julie Donaghey, Philippe Kieffer-Kwon, et al. · Cancer Research
Abstract 893: A chimeric PD1-CD28 switch receptor enhances the activity of TRuC-T cells
2020 · Derrick P. McCarthy, Sarah Guyette, et al. · Cancer Research
Abstract 4634: Novel dual HDAC & PI3K inhibitor, CUDC-907, for MYC-driven malignancies
2016 · Kaiming Sun, Ruzanna Atoyan, et al. · Cancer Research
Abstract 5502: IAP inhibitor CUDC-427 induces tumor regression or stasis in preclinical models of B cell lymphoma
2015 · Ze Tian, Kaiming Sun, et al. · Cancer Research
Abstract 4324: Predictive biomarker signatures for IAP inhibitor CUDC-427
2015 · Kaiming Sun, Ze Tian, et al. · Cancer Research
Abstract B100: Structure-based design of AZ7732 a novel in vivo active beta-alanine-derived pan-IAP inhibitor.
2013 · Jamal C. Saeh, Brian Aquila, et al. · Molecular Cancer Therapeutics
Works count: 23
Citation count: 314
H-index: 6
I10-index: 4
Year
Topic
Type